Literature DB >> 30610590

A Novel Regulatory Function of Long Non-coding RNAs at Different Levels of Gene Expression in Multiple Sclerosis.

Jalal Gharesouran1, Mohammad Taheri2, Arezou Sayad1, Soudeh Ghafouri-Fard1, Mehrdokht Mazdeh3, Mir Davood Omrani4.   

Abstract

Long non-coding RNAs (lncRNAs) play critical roles in regulation of immunological pathways. Consequently, their expression profile represents new biomarkers for susceptibility and progression of immunological disorders. However, their role in chronic inflammatory diseases such as multiple sclerosis (MS) remained unknown. Here, we assessed the expression of lncRNAs MALAT1 and HOTAIRM1 as well as their target genes in peripheral blood of MS patients to show their possible roles in disease initiation and progression. In this study, 50 patients with relapsing-remitting MS and 50 healthy matched controls were enrolled. Comparative Ct method via TaqMan assay was used to quantify transcript levels of MALAT1, HOTAIRM1, AGO2, CSTF2, CPSF7, and WDR33. Our analysis depicted significant differences in lncRNAs and their target genes expression levels. AGO2 expression was significantly elevated in MS patients (P < 0.001) whereas, CSTF2 expiration was considerably down-regulated (P < 0.042). These findings suggest that AGO2 and CSTF2 can be considered as potential theoretical biomarkers for MS and can be helpful for diagnosis and prognosis of responding patients to interferon.

Entities:  

Keywords:  AGO2; CPSF7; CSTF2; HOTAIRM1; MALAT1; Multiple sclerosis; WDR33

Mesh:

Substances:

Year:  2019        PMID: 30610590     DOI: 10.1007/s12031-018-1248-2

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  7 in total

1.  The Putative Association of TOB1-AS1 Long Non-coding RNA with Immune Tolerance: A Study on Multiple Sclerosis Patients.

Authors:  Reyhaneh Dehghanzad; Majid Pahlevan Kakhki; Asieh Alikhah; Mohammad Ali Sahraian; Mehrdad Behmanesh
Journal:  Neuromolecular Med       Date:  2019-09-03       Impact factor: 3.843

Review 2.  An Update on Diagnostic Laboratory Biomarkers for Multiple Sclerosis.

Authors:  Marwa Kaisey; Ghazal Lashgari; Justyna Fert-Bober; Daniel Ontaneda; Andrew J Solomon; Nancy L Sicotte
Journal:  Curr Neurol Neurosci Rep       Date:  2022-10-21       Impact factor: 6.030

Review 3.  Epigenomic and transcriptomic analysis of chronic inflammatory diseases.

Authors:  Sabrina Ka Man Tam; Danny Chi Yeu Leung
Journal:  Genes Genomics       Date:  2021-02-27       Impact factor: 1.839

4.  Cleavage Stimulation Factor Subunit 2: Function Across Cancers and Potential Target for Chemotherapeutic Drugs.

Authors:  Linfei Feng; Fengyang Jing; Xiaofeng Qin; Liming Zhou; Yujie Ning; Jun Hou; Weihao Kong; Youming Zhu
Journal:  Front Pharmacol       Date:  2022-03-18       Impact factor: 5.810

5.  CSTF2 Acts as a Prognostic Marker Correlated with Immune Infiltration in Hepatocellular Carcinoma.

Authors:  Wang Zhang; Yipeng Wan; Yue Zhang; Qi Liu; Xuan Zhu
Journal:  Cancer Manag Res       Date:  2022-09-12       Impact factor: 3.602

6.  Integrating the Ribonucleic Acid Sequencing Data From Various Studies for Exploring the Multiple Sclerosis-Related Long Noncoding Ribonucleic Acids and Their Functions.

Authors:  Zhijie Han; Jiao Hua; Weiwei Xue; Feng Zhu
Journal:  Front Genet       Date:  2019-11-12       Impact factor: 4.599

Review 7.  Long Non-Coding RNAs, Novel Offenders or Guardians in Multiple Sclerosis: A Scoping Review.

Authors:  Abbas Jalaiei; Mohammad Reza Asadi; Hani Sabaie; Hossein Dehghani; Jalal Gharesouran; Bashdar Mahmud Hussen; Mohammad Taheri; Soudeh Ghafouri-Fard; Maryam Rezazadeh
Journal:  Front Immunol       Date:  2021-12-07       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.